Abstract：
Herpes zoster (HZ, shingles) is a frequent medical condition which may severely impact the quality of life of affected patients. Different therapeutic approaches to treat acute HZ are available. The aim of this European project was the elaboration of a consensus-based guideline on the management of patients who present with HZ, considering different patient populations and different localizations. This interdisciplinary guideline aims at an improvement of the outcomes of the acute HZ management concerning disease duration, acute pain and quality of life of the affected patients and at a reduction of the incidence of postherpetic neuralgia and other complications. The guideline development followed a structured and predefined process, considering the quality criteria for guidelines development as suggested by the AGREE II instrument. The steering group was responsible for the planning and the organization of the guideline development process (Division of Evidence based Medicine, dEBM). The expert panel was nominated by virtue of clinical expertise and/or scientific experience and included experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, neurology and anaesthesiology. Recommendations for clinical practice were formally consented during the consensus conference, explicitly considering different relevant aspects. The guideline was approved by the commissioning societies after an extensive internal and external review process. In this first part of the guideline, diagnostic means have been evaluated. The expert panel formally consented recommendations for the management of patients with (suspected) HZ, referring to the assessment of HZ patients, considering various specific clinical situations. Users of the guideline must carefully check whether the recommendations are appropriate for the context of intended application. In the setting of an international guideline, it is generally important to consider different national approaches and legal circumstances with regard to the regulatory approval, availability and reimbursement of diagnostic and therapeutic interventions.
摘要：
带状疱疹（HZ，带状疱疹）是一种常见的医疗状况，可能会严重影响受影响患者的生活质量。治疗急性HZ的不同治疗方法是可用的。该欧洲项目的目的是制定一项基于共识的指南，以管理存在HZ的患者，考虑不同的患者人群和不同的本地化。本跨学科指南旨在改善关于疾病持续时间的急性HZ管理的结果。急性疼痛和受影响患者的生活质量，并减少带状疱疹后神经痛和其他并发症的发生率。指南的制定遵循了一个结构化和预定义的过程，考虑AGREEII文书建议的指南开发质量标准。指导小组负责指南制定过程的计划和组织（循证医学，dEBM)。专家小组是根据临床专业知识和/或科学经验提名的，包括皮肤病学领域的专家，病毒学/感染学，眼科,耳鼻喉科,神经病学和麻醉学。在共识会议期间正式同意了临床实践建议，明确考虑不同的相关方面。经过广泛的内部和外部审查程序，该指南已获得委托协会的批准。在指南的第一部分中，对诊断手段进行了评估。专家小组正式同意对(疑似)HZ患者的管理建议，提到对HZ患者的评估，考虑各种具体的临床情况。指南的用户必须仔细检查建议是否适合预期应用的上下文。在制定国际准则时，在监管批准方面，考虑不同的国家方法和法律环境通常很重要，诊断和治疗干预措施的可用性和报销。
